Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMALL 07/2003 Trial for Acute Lymphoblastic Leukemia
NCT00198991Phase 4Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Apr 2003
- Primary completion
- Jun 2011
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclophosphamide, dexamethasone, vincristine, daunorubicin, asparaginase escherichia coli and 13 more in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoints: Remission rate at day 46, Remission duration up to 10 years and 2 more. Started Apr 2003; status: completed.
02
Drugs
cyclophosphamidedexamethasonevincristinedaunorubicinasparaginase escherichia coli
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00198991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198991.